Key Points
- Avita Medical CFO David O'Toole bought 3,000 shares on Feb. 19 at an average price of $4.15, raising his direct stake to 140,127 shares (a 2.19% increase).
- The stock trades in the mid-single digits (opened $4.85) with a market cap of about $148.6M, a 12‑month range of $3.22–$10.29, and 50/200‑day SMAs of $3.84 and $4.25.
- Analysts' consensus is an average rating of "Hold" with a $5.50 target, and institutional investors own roughly 27.66% of the company after several funds added or increased positions.
Avita Medical Inc. (NASDAQ:RCEL - Get Free Report) CFO David O'toole acquired 3,000 shares of the business's stock in a transaction on Thursday, February 19th. The stock was acquired at an average cost of $4.15 per share, for a total transaction of $12,450.00. Following the transaction, the chief financial officer directly owned 140,127 shares in the company, valued at $581,527.05. The trade was a 2.19% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Avita Medical Trading Up 1.3%
NASDAQ:RCEL opened at $4.85 on Tuesday. The company has a market cap of $148.56 million, a price-to-earnings ratio of -2.77 and a beta of 1.78. Avita Medical Inc. has a twelve month low of $3.22 and a twelve month high of $10.29. The stock has a fifty day simple moving average of $3.84 and a 200-day simple moving average of $4.25.
Analyst Ratings Changes
RCEL has been the topic of a number of research analyst reports. D. Boral Capital restated a "buy" rating and issued a $10.00 target price on shares of Avita Medical in a research note on Tuesday, February 17th. Lake Street Capital boosted their price target on Avita Medical from $3.00 to $3.50 and gave the company a "hold" rating in a report on Friday, January 16th. Zacks Research upgraded Avita Medical from a "strong sell" rating to a "hold" rating in a report on Friday, December 19th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Avita Medical in a report on Monday, December 29th. Finally, BTIG Research raised Avita Medical from a "sell" rating to a "neutral" rating in a research report on Thursday, November 20th. One equities research analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $5.50.
Check Out Our Latest Analysis on Avita Medical
Institutional Trading of Avita Medical
Hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC bought a new stake in Avita Medical during the 1st quarter valued at $799,000. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Avita Medical during the 1st quarter worth $374,000. Jane Street Group LLC boosted its position in Avita Medical by 20.4% during the first quarter. Jane Street Group LLC now owns 63,744 shares of the company's stock valued at $519,000 after purchasing an additional 10,789 shares in the last quarter. Strs Ohio purchased a new position in Avita Medical in the first quarter valued at about $116,000. Finally, Rhumbline Advisers raised its holdings in Avita Medical by 8.8% in the second quarter. Rhumbline Advisers now owns 42,168 shares of the company's stock worth $223,000 after purchasing an additional 3,393 shares in the last quarter. Hedge funds and other institutional investors own 27.66% of the company's stock.
About Avita Medical
(
Get Free Report)
Avita Medical, Inc (NASDAQ: RCEL) is a regenerative medicine company focused on the development and commercialization of cell‐based therapies for acute and chronic wounds. Its flagship technology, the ReCell® Autologous Cell Harvesting Device, enables clinicians to create a suspension of a patient's own skin cells at the point of care. The system is designed to accelerate wound healing, minimize donor‐site requirements and reduce scarring for patients suffering from burns, traumatic wounds and a variety of surgical and reconstructive procedures.
Founded in 2009 and headquartered in Carlsbad, California, Avita Medical has secured regulatory clearances in key markets, including CE mark approval in the European Union and 510(k) clearance from the U.S.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
